Cisco upgraded, PepsiCo downgraded: Wall Street's top analyst calls
HSBC upgraded Cisco (CSCO) to Buy with a $133 target, citing strong Q1 results. Wells Fargo upgraded Zimmer Biomet (ZBH) to Overweight with a $123 target. Goldman Sachs upgraded United Natural Foods (UNFI) to Buy with a $60 target. Morgan Stanley upgraded Nucor (NUE) to Overweight with a $310 target. Bernstein downgraded PepsiCo (PEP) to Underperform with a $128 target. JPMorgan downgraded Tyson Foods (TSN) to Neutral with a $65 target.
How this was made

The 30-second read
Why it matters
The most actionable items are Cisco’s guidance raise paired with an upgrade, and PepsiCo’s downgrade tied to an expected earnings miss. Most other names are driven by analyst theses without additional new company data in the text.
Market read
Traders can use the Cisco and PepsiCo items for near-term sentiment and positioning, while the rest are lower-conviction thesis shifts from coverage changes.
What to watch
For several names, the article is thesis-only (valuation, regulatory path, product read-through). Traders should verify whether any of these notes coincide with upcoming earnings dates or concrete upcoming catalysts not mentioned here.
Background
The piece is a Wall Street analyst roundup featuring multiple rating upgrades/downgrades and price-target changes across industrials, healthcare, consumer, and retail, plus one explicit mention of Cisco raising fiscal 2027 guidance after strong fiscal Q1 results.
Ticker impact
HSBC upgraded Cisco to Buy and raised its price target after Cisco reported strong fiscal Q1 results and lifted fiscal 2027 earnings guidance.
Likely upward pressure as the market reprices Cisco’s earnings outlook and the Street’s stance.
The article cites both an analyst rating/target change and a company-specific guidance raise, which are direct drivers for positioning.
Bernstein downgraded PepsiCo to Underperform and cut its price target, saying PepsiCo is expected to miss earnings expectations over the next 12 months.
Likely downside pressure as investors price in a higher probability of underperformance versus expectations.
The article provides a clear rating cut and a specific thesis about missing earnings expectations over the next year.
Wells Fargo upgraded Zimmer Biomet to Overweight and raised its price target, arguing Monogram should lift knee and worldwide growth.
Likely modest upside bias as the market reacts to improved growth outlook assumptions.
The catalyst is a product thesis (Monogram) plus a target raise, but the article lacks new company data beyond the analyst note.
Piper Sandler upgraded Medtronic to Overweight from Neutral, signaling improved expectations for the stock.
Likely mild upward pressure as positioning shifts toward the upgraded view.
The article states the upgrade but does not include a concrete new fundamental driver or numbers.
Goldman Sachs upgraded United Natural Foods to Buy and raised its price target, citing further runway for strong EBITDA growth.
Likely upward pressure as the market incorporates a stronger profitability path.
The thesis is specific (EBITDA runway) and includes a target change, but it is still analyst-driven rather than a new company disclosure.
Morgan Stanley upgraded Nucor to Overweight and raised its price target, increasing near-term steel price forecasts due to tight supply.
Likely upward pressure as investors reprice commodity-linked earnings sensitivity.
The article ties the upgrade to updated steel price forecasts, but does not provide new Nucor-specific operational data.
Wells Fargo upgraded Praxis Precision to Overweight and sharply raised its price target after an investor day, citing improved positivity on ulixacaltamide D56 results.
Likely strong upside bias as the market reacts to improved trial-result interpretation and a higher target.
The article references a specific trial result (D56) and a large target increase, but details are limited.
JPMorgan downgraded Tyson Foods to Neutral and raised its price target, saying the stock’s recovery better reflects fundamentals than the near-term outlook.
Likely limited upside or mild downside as the market discounts the downgrade’s caution.
The article includes both a downgrade and a thesis about what the stock move already reflects, but no new Tyson datapoint.
Market effects
Broad retail and consumer coverage initiations plus selective downgrades/upgrades can shift relative performance within consumer discretionary and staples.
Primarily US-listed single-name positioning; limited direct cross-region impact implied.
Minimal, as the catalysts are analyst notes and company-specific guidance rather than global macro shocks.
Counterpoint
Analyst rating changes may be partially priced in quickly; without new company disclosures (beyond Cisco’s guidance raise), follow-through may be limited.
Key entities
- companyCisco
Upgraded to Buy by HSBC with a raised price target after strong fiscal Q1 results and raised fiscal 2027 earnings guidance.
- companyPepsiCo
Downgraded to Underperform by Bernstein with a cut price target, citing expected earnings misses over the next 12 months.

